

October 20, 2021

Oxytocin Injection Synthetic 10 USP units/mL SD vial 1 mL
Backorder Notification

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to increased demand over the past few months as well as production delays, we will be experiencing a supply interruption on **Oxytocin Injection Synthetic 10 USP units/mL SD vial 1 mL**, effective, **November 1, 2021 to January 30, 2022**.

For the month of **November**, allocations will be reduced to 75% based on historical **1 mL** demand. In an effort to maximize coverage, Fresenius Kabi Canada will be providing allocations of **Oxytocin Injection Synthetic 10 USP units MD Vial 10 mL** to all customers throughout November. Allocations of the **10 mL** will be increased to cover 100% of historical 10 mL demand plus 25% of the 1mL demand on a mL per mL basis (1:10 conversion ratio). For example: 1 vial of 10 mL = 10 vials of 1 mL.

For the month of **December**, there will be **no stock of the 1mL remaining**. Allocations of the 10 mL will be further increased to cover 100% demand of the 10 mL plus 100% of the 1 mL demand on a mL per mL basis (1:10 conversion ratio).

For the month of **January**, we will have very limited stock of **10 mL** remaining and will only be able to cover the historical demand of the **10 mL**.

DIN	Fresenius Kabi Product Code	McKesson Product Code	Product Description	Supply Status November 2021	Supply Status December 2021	Supply Status January 2022
02139561	C912011	975965	Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL	75% Allocation	Backorder	Backorder
02139561	C1210	922626	Oxytocin Injection, USP Synthetic 10 USP units/mL MD Vial 10 mL	100% of historical 10 mL demand + 25% coverage of 1 mL demand on a mL per mL basis (1:10 conversion ratio)	100% of historical 10 mL demand + 100% coverage of 1 mL demand on a mL per mL basis (1:10 conversion ratio)	100% of historical 10 mL demand only


We recognize that the 10 mL is not an ideal substitution in many cases, however; it is the only measure available at this time. We have notified Health Canada as well as Pfizer of our impending shortage on Oxytocin. Pfizer has indicated that they have **limited inventory of their 1 mL ampoule** available to help cover the market shortage, however; they are unable to cover the total market demand.

We encourage all customers to use severe conservation measures across all formats of Oxytocin available to extend the supply as long as possible. We are working diligently with our plants to expedite production and will advise of updates should there be any improvements to the timelines and allocations indicated above.

We recognize the difficulties and inconvenience that you may encounter as a result of our supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact customer service at (877) 821-7724.

Sincerely,



 Vishakha Patel
 Senior Director, IV Drugs, Sales, Marketing & BD